The biotech firm reported a smaller-than-expected GAAP loss per share and reduced adjusted EBITDA loss for the quarter.
Fractyl Health posted a first-quarter GAAP loss per share of $0.06, beating expectations by $0.11. The result reflects a narrower loss compared to estimates and prior periods.
Adjusted EBITDA for the quarter ended March 31, 2026, was -$18.0 million, an improvement from -$23.0 million in the same period last year. The company attributed the reduction to lower non-GAAP adjusted losses.
No immediate market reaction was disclosed in the release.